Alfresa <2784> continues to rise. It has announced a capital business alliance with Innova cell. Innova cell is developing regenerative medical products targeting fecal incontinence and urinary incontinence, and is currently conducting phase 3 clinical trials of regenerative medical products "ICEF15" for the treatment of urge fecal incontinence. The company plans to support the establishment of a distribution system in Japan after the launch of "ICEF15" through this contract. There is a sense of anticipation that this will lead to an expansion in the regenerative medical field. It seems that they will invest 1 billion yen, resulting in a 4.2% stake.
アルフレッサ---続伸、再生医療製品開発手掛けるイノバセルと資本業務提携
Alfresa continues to rise, forming a capital business alliance with Innova Cell, which is involved in the development of regenerative medical supplies.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated